Alps Group Revenue Jumps 44% to $4.9M, Net Loss Narrows in Fiscal 2026
ALPS is trading near its 52-week low of $0.38 (6.6% above the low) on light trading volume (0.1× avg).
Summary
Alps Group reported fiscal 2026 revenue of $4.9 million, up 44% year-over-year, driven by growth across cellular therapy, medical testing, and aesthetics services. Net loss narrowed to $2.1 million from $2.6 million, with gross profit rising to $1.6 million despite a margin dip to 32% due to mix shift. The company completed its Nasdaq listing via a business combination in October 2025 and advanced its NK cell therapy program toward process validation. R&D spending was cut sharply as the COVID-19 vaccine candidate was discontinued, while administrative costs rose on professional fees tied to the listing. The results show improving top-line momentum and cost discipline, though the stock trades at $0.405 with a $69 million market cap and faces a Nasdaq minimum bid price compliance issue flagged in May 2026.
At the time of this announcement, ALPS was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.1M. The 52-week trading range was $0.38 to $15.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.